Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Visa Inc (V) Price & Performance

BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Visa Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Visa Inc trades at $362.79 (market cap $668.96B). The key difference: Visa Inc is far larger — about 40.3× BridgeBio Pharma Inc's market cap, and Visa Inc pays a 0.74% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOV
Market Cap
$16.61B$668.96B
Sector
HealthFinancials
52-Week High
$90.17$370.47
52-Week Low
$47.29$295.52
Enterprise Value
$18.16B$679.54B
Volume
10,431,336
Dividend Yield
0.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Visa Inc

Visa (V) trades at $361.32, down 0.33% on the day, with strong fundamentals including 50.78% net income margin and consistent earnings beats. The stock shows bearish technical signals but maintains bullish moving averages. Recent developments include AI-powered commerce initiatives and stablecoin partnerships, positioning Visa for future payment system evolution. Financial trends show revenue growth from $29.3B in 2022 to $40B in 2025, with robust cash flow generation.

Visa presents a compelling long-term investment with 85% analyst buy ratings and $426.31 consensus price target suggesting 18% upside. Key risks include fintech competition and regulatory pressures, but the company's dominant market position, high profitability, and innovation in digital payments support continued growth potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Visa Inc

Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.

Read more on V